186 related articles for article (PubMed ID: 34383102)
21. Hydroxyurea Treated β-Thalassemia Children Demonstrate a Shift in Metabolism Towards Healthy Pattern.
Iqbal A; Ansari SH; Parveen S; Khan IA; Siddiqui AJ; Musharraf SG
Sci Rep; 2018 Oct; 8(1):15152. PubMed ID: 30310134
[TBL] [Abstract][Full Text] [Related]
22. Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea.
Dover GJ
Ann N Y Acad Sci; 1998 Jun; 850():80-6. PubMed ID: 9668530
[TBL] [Abstract][Full Text] [Related]
23. Response to hydroxycarbamide in pediatric β-thalassemia intermedia: 8 years' follow-up in Egypt.
El-Beshlawy A; El-Ghamrawy M; EL-Ela MA; Said F; Adolf S; Abdel-Razek AR; Magdy RI; Abdel-Salam A
Ann Hematol; 2014 Dec; 93(12):2045-50. PubMed ID: 25062719
[TBL] [Abstract][Full Text] [Related]
24. The use of hydroxyurea in the real life of MIOT network: an observational study.
Ricchi P; Meloni A; Rigano P; Pistoia L; Spasiano A; Allò M; Messina G; Quarta A; Rosso R; Quota A; Filosa A; Maggio A; Pepe A
Expert Opin Drug Saf; 2022 Nov; 21(11):1433-1440. PubMed ID: 35435090
[TBL] [Abstract][Full Text] [Related]
25. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D
Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of hydroxyurea in providing transfusion independence in β-thalassemia.
Ansari SH; Shamsi TS; Ashraf M; Perveen K; Farzana T; Bohray M; Erum S; Mehboob T
J Pediatr Hematol Oncol; 2011 Jul; 33(5):339-43. PubMed ID: 21602718
[TBL] [Abstract][Full Text] [Related]
27. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
28. Use of hydroxyurea and recombinant erythropoietin in management of homozygous beta0 thalassemia.
Kohli-Kumar M; Marandi H; Keller MA; Guertin K; Hvizdala E
J Pediatr Hematol Oncol; 2002 Dec; 24(9):777-8. PubMed ID: 12468925
[TBL] [Abstract][Full Text] [Related]
29. Hydroxyurea in the management of thalassemia intermedia.
Karimi M
Hemoglobin; 2009; 33 Suppl 1():S177-82. PubMed ID: 20001623
[TBL] [Abstract][Full Text] [Related]
30. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
[TBL] [Abstract][Full Text] [Related]
31. Hematologic response to hydroxyurea therapy in children with beta-thalassemia major.
Mtvarelidze Z; Kvezereli-Kopadze A; Kvezereli-Kopadze M; Mestiashvili I
Georgian Med News; 2008 Mar; (156):91-4. PubMed ID: 18403819
[TBL] [Abstract][Full Text] [Related]
32. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia.
Bradai M; Abad MT; Pissard S; Lamraoui F; Skopinski L; de Montalembert M
Blood; 2003 Aug; 102(4):1529-30. PubMed ID: 12702505
[TBL] [Abstract][Full Text] [Related]
33. Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort Study.
Kolliopoulou A; Siamoglou S; John A; Sgourou A; Kourakli A; Symeonidis A; Vlachaki E; Chalkia P; Theodoridou S; Ali BR; Katsila T; Patrinos GP; Papachatzopoulou A
Hemoglobin; 2019 Jan; 43(1):27-33. PubMed ID: 31039620
[TBL] [Abstract][Full Text] [Related]
34. Hydroxyurea Treatment in Transfusion-Dependent β-Thalassemia Patients.
Bordbar MR; Silavizadeh S; Haghpanah S; Kamfiroozi R; Bardestani M; Karimi M
Iran Red Crescent Med J; 2014 Jun; 16(6):e18028. PubMed ID: 25068055
[TBL] [Abstract][Full Text] [Related]
35. The activity of superoxide dismutase in hydroxyurea-treated E beta thalassemia.
Ajanta H; Chakraborty S; Madhusnata D; Bhattacharya DK; Manisha D
J Assoc Physicians India; 2002 Aug; 50():1034-5. PubMed ID: 12421025
[TBL] [Abstract][Full Text] [Related]
36. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
[TBL] [Abstract][Full Text] [Related]
37. Hydroxyurea for hemoglobin E/β-thalassemia: a systematic review and meta-analysis.
Algiraigri AH; Kassam A
Int J Hematol; 2017 Dec; 106(6):748-756. PubMed ID: 28786080
[TBL] [Abstract][Full Text] [Related]
38. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia.
Bradai M; Pissard S; Abad MT; Dechartres A; Ribeil JA; Landais P; de Montalembert M
Transfusion; 2007 Oct; 47(10):1830-6. PubMed ID: 17880608
[TBL] [Abstract][Full Text] [Related]
39. Blood transfusion versus hydroxyurea in beta-thalassemia in Iran: a cost-effectiveness study.
Ravangard R; Mirzaei Z; Keshavarz K; Haghpanah S; Karimi M
Hematology; 2018 Aug; 23(7):417-422. PubMed ID: 29157136
[TBL] [Abstract][Full Text] [Related]
40. Gγ-Xmn I polymorphism: a significant determinant of β-thalassemia treatment without blood transfusion.
Ansari SH; Shamsi TS; Munzir S; Khan MT; Erum S; Perveen K; Farzana T; Ashraf M; Mehboob T; Moinuddin M
J Pediatr Hematol Oncol; 2013 May; 35(4):e153-6. PubMed ID: 23389500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
